OBJECTIVE The aim of current study was to prepare and characterize novel iron heparin nanoparticles.METHODS Iron heparin nanopaticles were obtained through ionic complexation between Fe3+ and heparin.Iron heparin nanoparticles were characterized using dynamic light scattering(DLS),Zeta potential,scanning force microscopy(SFM) and fourier infrared spectroscopy(FT-IR).The content of heparin of iron heparin nanoparticles were determined by toluidine blue heparin assay.The anticoagulant activity of iron heparin nanoparticles were tested by activated partial thromboplastin time(APTT) assay.RESULTS Size(139.0-219.9) nm and Zeta potential(-22.5——36.5) mV of iron heparin nanoparticles were conveniently modulated by varying ratio of Fe3+ and heparin.IR result showed Fe3+ interacted with O-sulphate groups.The content of heparin of iron heparin nanoparicles were in range of 29.5%-33.1% and anticoagulant activity of iron heparin nanoparicles were in range of 43.2～46.5 u·mg-1 by varying ratio of Fe3+ and heparin.CONCLUSION Novel anticoagulant iron heparin nanoparticles were fabricated by using only complexation of Fe3+ and heparin.
YU Lu;GO Yn-gung;FU Hu;LIU Meng;LIU Sho-qin;DI Zhi-fei.
Preparation and Characterization of Novel Anticoagulant Iron Heparin Nanopariticles [J]. Chinese Pharmaceutical Journal, 2008, 43(20): 1535-1537
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HIRSH J，WARKENTIN T E，RASCHKE R，et al. Heparin and low-molecular-weight-heparin [J] .Chest，1998，114(5)：489-510.
[2] GU J，YANG J，ZHANG C Y，et al. Compare of mulecule characteristics and bioactivity of low molecular weight heparin products in market[J] .Chin Pharm J(中国药学杂志)，2007，42（6）：461-465.
[3] HIRSH J， ANAND S S， HALPERIN J L， et al. Guide to anti- coagulant therapy：heparin a statement for healthcare professionals from the American heart association[J] . Circulation，2001，103(24)：2994-3018.
[4] MCAVOY T J. The biologic half-life of heparin [J] .Clin Pharmacol Ther，1979，25（3）：372-379.
[5] PETITOU M，HERAULT J P，BERNAT A，et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects[J] . Nature，1999，398(6726)：417-422.
[6] MENG L，XIULI Y，ZHIFEI D，et al. Stabilized hemocompatible coating of nitinol devices based on Photo-Cross-Linked Alginate/Heparin Multilayer[J] .Lanbmuir，2007,23(18)：9378-9385.
[7] GRANT D，LONG W F，WILLIAMSON F B. Infrared spectro scopy of heparin-cation complexes[J] . Biochem J，1987，244(1)：143-149.
[8] MOGHIMI S M，HUNTER A C，MURRAY J C. Long-circulating and target-specific nanoparticles：theory to practice[J] . Pharmacol Rev，2001，53(2)：283-318.
[9] SIPOS P，BERKESI O，TOMBACZ E，et al. Formation of sph-erical iron(Ⅲ) oxyhydroxide nanoparticles sterically stabilized by chitosan in aqueous solutions[J] .J Inorg Biochem，2003，95(1)：55-63.
[10] LEVER R，PAGE C P. Novel drug development opportunities for heparin[J] .Nat Rev Drug Discov，2002，1(2)：140-148.
